Crystalline form of compound and method of producing crystalline form of compound
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- VIKING THERAPEUTICS INC
- Filing Date
- 2024-01-11
- Publication Date
- 2026-06-03
AI Technical Summary
There is a need for improved crystalline forms of thyroid hormone receptor β (TRβ) agonists to facilitate pharmaceutical development and enhance their stability and efficacy in treating conditions such as adrenoleukodystrophy (ALD) and lipid disorders.
The development of crystalline forms of TRβ agonists, including tert-butyl methyl ether (TBME) solvate, toluene solvate, ethanol solvate, tetrahydrofuran (THF) solvate, ethyl acetate (EtOAc) solvate, acetone solvate, and unsolvated crystalline Form C, which exhibit improved stability, processability, and low water adsorption, achieved through controlled crystallization methods.
These crystalline forms provide long-term stability, ease of manufacture, and effective treatment of ALD and lipid disorders like hypercholesterolemia and fatty liver disease, with unsolvated Form C demonstrating non-hygroscopic properties and high melting point, ensuring clinical efficacy.
Smart Images

Figure 2024028460000001